Medical lens company STAAR Surgical (NASDAQ: STAA) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 120% year on year to $93.52 million. Its non-GAAP profit of $0.29 per share was significantly above analysts’ consensus estimates.

Is now the time to buy STAA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

STAAR Surgical’s first quarter performance was met with a strong positive market reaction, reflecting the company’s progress in resolving prior operational disruptions and inventory challenges. Management credited this turnaround to robust sales in China, early momentum from the EVO+ lens launch, and a return to normalized distributor inventory levels. Interim Co-CEO Warren Foust emphasized, “We have now largely moved past many of the challenges that we faced in 2025...those issues are behind us.” Improved execution across major markets, particularly in the United States, and disciplined spending contributed to the company’s return to profitability.

Looking forward, management sees several factors shaping STAAR Surgical’s trajectory, including continued adoption of EVO+ in China, expanded U.S. market access, and operational efficiencies from the scaling of the Swiss manufacturing facility. While the team is optimistic about maintaining momentum, they remain cautious given macroeconomic and geopolitical uncertainties. As Interim Co-CEO Deborah Andrews explained, “We expect to have a good Q2...but we’re kind of cautious about giving guidance or anything like that, at least in the short term, and we’ll revisit it later on in the year.” The company intends to balance growth opportunities with ongoing cost discipline and manufacturing enhancements.

Key Insights from Management’s Remarks

Management attributed the quarter's results to stabilization in China, a successful product launch, and improved cost control, while also highlighting operational advances and a more stable market environment.

• China sales normalization: STAAR Surgical resolved elevated channel inventory in China, with distributor levels now at or below contractual targets. Management reported that end market demand now closely matches sales into the market, which they believe provides a stable base for future quarters.

• EVO+ ICL launch drives demand: Strong early adoption of the EVO+ lens in China supported revenue growth and required increased output from the company’s Swiss manufacturing site. Management noted that EVO+ is positioned as a premium product and that customers are accepting the price premium associated with it.

• U.S. market expansion: The U.S. posted its first quarter above $6 million in sales, aided by expanded FDA approval for EVO ICL to patients aged 45 to 60. Management sees the U.S. as an underpenetrated market with long-term growth potential, supported by increased surgeon adoption and improved commercial execution.

• Operational discipline and cost actions: Cost reduction efforts initiated in 2025 translated into lower operating expenses and improved margins. The gross profit margin increase was attributed to manufacturing efficiencies in Switzerland, reduced period costs, and lower inventory provisions.

• Manufacturing and systems upgrades: The Nidau, Switzerland facility is on track to supply 100% of lenses to China in 2026, avoiding import tariffs. The ongoing rollout of a new Oracle ERP system is expected to further improve business visibility and scalability.

Drivers of Future Performance

STAAR Surgical’s outlook hinges on continued product adoption, manufacturing scale-up, and the ability to navigate external risks, particularly in China and the U.S.

• EVO+ adoption in China: Management expects further growth from the uptake of EVO+ lenses, which command a premium price and have shown strong early demand. The ability to meet this demand depends on production scaling at the Swiss facility; management anticipates full supply alignment by the end of Q2.

• U.S. market penetration: The recent FDA approval expanding the addressable patient age range should enable incremental growth. However, management recognizes that broader U.S. adoption depends on continued surgeon engagement and shifts from laser-based procedures to lens-based refractive surgery.

• Cautious approach to guidance: Despite recent operational improvements, management refrained from issuing formal forward-looking guidance due to lingering macroeconomic and geopolitical uncertainties. They cited potential volatility in China’s refractive market and external disruptions in Europe, the Middle East, and India as ongoing risks.

Catalysts in Upcoming Quarters

In coming quarters, StockStory analysts will be closely monitoring (1) the pace and sustainability of EVO+ adoption in China and whether normalized inventory levels persist, (2) execution on scaling Swiss manufacturing to meet global demand and optimize margins, and (3) evidence of continued growth in the U.S. market following the recent regulatory expansion. Progress on ERP integration and efficiency improvements will also be important markers of operational scalability.

STAAR Surgical currently trades at $35.30, up from $29.41 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.